Corbus Pharmaceuticals Holdings Inc
CRBP9.340USD
+0.030+0.32%
收盘 08/04, 16:00（美东）报价延迟15分钟
114.25M总市值
亏损市盈率 TTM
关于 Corbus Pharmaceuticals Holdings Inc 公司
Corbus Pharmaceuticals Holdings, Inc. 是一家拥有多元化投资组合的精准肿瘤学公司。该公司的产品线由两种针对实体瘤的实验性药物组成：CRB-701，这是一种抗体药物偶联物 (ADC)，靶向癌细胞上 Nectin-4 的表达以释放细胞毒性有效载荷；CRB-601，这是一种抗整合素单克隆抗体，可阻断癌细胞上表达的 TGFβ 的激活。其产品线还包括 CRB-913，这是一种高度外周限制的大麻素 1 型 (CB1) 受体反向激动剂，用于治疗肥胖症。该公司已从加州大学旧金山分校的 Stephen Nishimura 博士的实验室获得了 CRB-601 的知识产权。该公司不拥有或经营制造设施，而是依靠第三方合同制造组织或许可合作伙伴为其提供用于临床前和临床研究以及商业活动的药物。
公司简介
公司代码CRBP
公司名称Corbus Pharmaceuticals Holdings Inc
上市日期Oct 24, 2014
CEODr. Yuval Cohen, Ph.D.
员工数量28
证券类型Ordinary Share
年结日Oct 24
公司地址500 River Ridge Drive
城市NORWOOD
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02062
电话16179630103
网址https://www.corbuspharma.com/
公司代码CRBP
上市日期Oct 24, 2014
CEODr. Yuval Cohen, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Sean F. Moran, CPA
Mr. Sean F. Moran, CPA
Chief Financial Officer
Chief Financial Officer
15.68K
-52.68%
Dr. Yuval Cohen, Ph.D.
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
14.63K
-77.23%
Mr. Alan F. Holmer, J.D.
Mr. Alan F. Holmer, J.D.
Independent Director
Independent Director
7.85K
+157.58%
Dr. Dominic Smethurst
Dr. Dominic Smethurst
Chief Medical Officer
Chief Medical Officer
6.11K
-92.09%
Dr. Yong Ben, M.D., Ph.D.
Dr. Yong Ben, M.D., Ph.D.
Independent Director
Independent Director
4.80K
--
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board
4.80K
--
Dr. Anne Altmeyer, Ph.D.
Dr. Anne Altmeyer, Ph.D.
Independent Director
Independent Director
3.41K
--
Dr. Ian Hodgson
Dr. Ian Hodgson
Chief Operating Officer
Chief Operating Officer
1.23K
--
Dr. John Kenneth Jenkins, M.D.
Dr. John Kenneth Jenkins, M.D.
Independent Director
Independent Director
--
--
Mr. Winston W. Kung
Mr. Winston W. Kung
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Sean F. Moran, CPA
Mr. Sean F. Moran, CPA
Chief Financial Officer
Chief Financial Officer
15.68K
-52.68%
Dr. Yuval Cohen, Ph.D.
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
14.63K
-77.23%
Mr. Alan F. Holmer, J.D.
Mr. Alan F. Holmer, J.D.
Independent Director
Independent Director
7.85K
+157.58%
Dr. Dominic Smethurst
Dr. Dominic Smethurst
Chief Medical Officer
Chief Medical Officer
6.11K
-92.09%
Dr. Yong Ben, M.D., Ph.D.
Dr. Yong Ben, M.D., Ph.D.
Independent Director
Independent Director
4.80K
--
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board
4.80K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月28日 周一
更新时间: 7月28日 周一
持股股东
股东类型
持股股东
持股股东
占比
Cormorant Asset Management, LP
19.41%
OrbiMed Advisors, LLC
9.58%
Octagon Capital Advisors LP
9.11%
BlackRock Institutional Trust Company, N.A.
6.46%
The Vanguard Group, Inc.
4.90%
Other
50.54%
持股股东
持股股东
占比
Cormorant Asset Management, LP
19.41%
OrbiMed Advisors, LLC
9.58%
Octagon Capital Advisors LP
9.11%
BlackRock Institutional Trust Company, N.A.
6.46%
The Vanguard Group, Inc.
4.90%
Other
50.54%
股东类型
持股股东
占比
Hedge Fund
49.09%
Investment Advisor
16.03%
Investment Advisor/Hedge Fund
12.17%
Private Equity
9.58%
Venture Capital
3.52%
Bank and Trust
1.74%
Research Firm
1.40%
Individual Investor
0.61%
Pension Fund
0.07%
Other
5.79%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
246
11.50M
94.01%
-3.45M
2025Q1
251
11.62M
94.98%
-3.51M
2024Q4
256
12.27M
100.79%
-2.94M
2024Q3
245
12.92M
107.22%
+703.14K
2024Q2
212
12.40M
115.98%
+3.38M
2024Q1
167
10.08M
102.86%
+5.32M
2023Q4
134
960.97K
21.74%
-489.88K
2023Q3
143
765.13K
17.31%
-695.27K
2023Q2
165
756.43K
17.12%
-730.85K
2023Q1
205
764.30K
18.94%
-373.63K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Cormorant Asset Management, LP
2.38M
19.41%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
1.17M
9.58%
--
--
Mar 31, 2025
Octagon Capital Advisors LP
1.11M
9.11%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
790.90K
6.46%
-27.90K
-3.41%
Mar 31, 2025
The Vanguard Group, Inc.
672.06K
5.49%
+12.86K
+1.95%
Mar 31, 2025
Prosight Capital
575.14K
4.7%
+305.14K
+113.01%
Mar 31, 2025
RA Capital Management, LP
430.18K
3.52%
+430.18K
--
Feb 02, 2024
Paradigm BioCapital Advisors LP
399.66K
3.27%
+399.66K
--
Jan 26, 2024
Renaissance Technologies LLC
345.20K
2.82%
+206.10K
+148.17%
Mar 31, 2025
Exome Asset Management LLC
289.69K
2.37%
+289.69K
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.02%
Pacer WealthShield ETF
0%
Harbor Health Care ETF
0%
ProShares Hedge Replication ETF
0%
Tema Oncology ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Vanguard US Momentum Factor ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.02%
Pacer WealthShield ETF
占比0%
Harbor Health Care ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Tema Oncology ETF
占比0%
Schwab U.S. Broad Market ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Vanguard US Momentum Factor ETF
占比0%
Fidelity Enhanced Small Cap ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
公告日期
类型
比率
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
